DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Aplaviroc

Aplaviroc

  • Review CCR5 Antagonists: Host-Targeted Antivirals for the Treatment of HIV Infection

    Review CCR5 Antagonists: Host-Targeted Antivirals for the Treatment of HIV Infection

  • Aplaviroc (APL, 873140)

    Aplaviroc (APL, 873140)

  • A Novel Small Molecule CCR5 Inhibitor Active Against R5-Tropic HIV-1S

    A Novel Small Molecule CCR5 Inhibitor Active Against R5-Tropic HIV-1S

  • Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology Xuanmao Jiao1, Omar Nawab1,2,Tejal Patel2, Andrew V

    Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology Xuanmao Jiao1, Omar Nawab1,2,Tejal Patel2, Andrew V

  • Background Paper 6.7 Human Immunodeficiency Virus (HIV)/ Acquired Immune Deficiency Syndromes (AIDS)

    Background Paper 6.7 Human Immunodeficiency Virus (HIV)/ Acquired Immune Deficiency Syndromes (AIDS)

  • Full Article In

    Full Article In

  • HIV Entry Inhibitors Stuck in the Pipeline

    HIV Entry Inhibitors Stuck in the Pipeline

  • Antiviral Activity and Safety of Aplaviroc with Lamivudine/Zidovudine in HIV-Infected, Therapy-Naive Patients: the ASCENT (CCR102881) Study

    Antiviral Activity and Safety of Aplaviroc with Lamivudine/Zidovudine in HIV-Infected, Therapy-Naive Patients: the ASCENT (CCR102881) Study

  • Stembook 2018.Pdf

    Stembook 2018.Pdf

  • Hepatotoxicity of Contemporary Antiretroviral Drugs: a Review and Evaluation of Published Clinical Data

    Hepatotoxicity of Contemporary Antiretroviral Drugs: a Review and Evaluation of Published Clinical Data

  • CCR5 Inhibitors and HIV-1 Infection

    CCR5 Inhibitors and HIV-1 Infection

  • Repurposing of FDA Approved Drugs

    Repurposing of FDA Approved Drugs

  • Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology

    Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology

  • Ccr5 Antagonists in the Treatment of Treatment-Naïve Patients Infected with Ccr5 Tropic Hiv-1

    Ccr5 Antagonists in the Treatment of Treatment-Naïve Patients Infected with Ccr5 Tropic Hiv-1

  • Research Trends and Regulation of CCL5 in Prostate Cancer

  • BHIVA) Guidelines for the Treatment of HIV-Infected Adults with Antiretroviral Therapy (2006

  • WO 2017/035230 Al 2 March 2017 (02.03.2017) P O P C T

    WO 2017/035230 Al 2 March 2017 (02.03.2017) P O P C T

  • HIV-1 Entry Inhibition by Small-Molecule CCR5 Antagonists: a Combined Molecular Modeling and Mutant Study Using a High-Throughput Assay

    HIV-1 Entry Inhibition by Small-Molecule CCR5 Antagonists: a Combined Molecular Modeling and Mutant Study Using a High-Throughput Assay

Top View
  • Parenteral Inhibitors of HIV Entry in Current Development The
  • HIV-1 Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Non-B Subtypes
  • HIV-1 Entry, Inhibitors, and Resistance
  • New Antiretroviral Therapies and Potential Drug Interactions in HIV
  • Mechanisms of Ccr5 Agonist/Antagonist Inhibition of Hiv-1
  • The Role of Receptors in the Hiv-1 Entry Process
  • Antiviral Effects of Polyphenols from Marine Algae
  • HIV-1 Entry and Prospects for Protecting Against Infection
  • Human Immunodeficiency Virus
  • Study Protocol and Results
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
  • Combinatorial Anti-HIV Gene Therapy: Using a Multipronged Approach to Reach Beyond HAART
  • Chemical Properties Biological Description Solubility Information
  • Aplaviroc | Medchemexpress
  • Co-Receptor Signaling in the Pathogenesis of Neurohiv
  • WO 2017/205585 Al 30 November 20 7 (30
  • The Expanding Therapeutic Perspective of CCR5 Blockade
  • Immunology/Inflammation


© 2024 Docslib.org    Feedback